Wall Street analysts forecast that bluebird bio, Inc. (NASDAQ:BLUE) will post earnings per share of ($1.64) for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for bluebird bio’s earnings, with the lowest EPS estimate coming in at ($2.10) and the highest estimate coming in at ($0.78). bluebird bio reported earnings of ($1.88) per share during the same quarter last year, which indicates a positive year over year growth rate of 12.8%. The firm is scheduled to issue its next quarterly earnings report on Wednesday, February 28th.

On average, analysts expect that bluebird bio will report full-year earnings of ($6.72) per share for the current financial year, with EPS estimates ranging from ($7.27) to ($5.44). For the next fiscal year, analysts anticipate that the company will report earnings of ($6.85) per share, with EPS estimates ranging from ($7.85) to ($3.53). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that that provide coverage for bluebird bio.

bluebird bio (NASDAQ:BLUE) last announced its earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.68) by ($0.05). bluebird bio had a negative net margin of 883.18% and a negative return on equity of 28.79%. The business had revenue of $7.71 million for the quarter, compared to the consensus estimate of $8.47 million. During the same period in the prior year, the business posted ($2.07) EPS. bluebird bio’s revenue for the quarter was up 397.4% on a year-over-year basis.

BLUE has been the subject of a number of analyst reports. Wedbush reaffirmed an “outperform” rating and set a $174.00 target price (up previously from $135.00) on shares of bluebird bio in a research note on Thursday, November 2nd. Cantor Fitzgerald reaffirmed a “sell” rating and set a $39.00 target price on shares of bluebird bio in a research note on Thursday, September 28th. Evercore ISI raised shares of bluebird bio from an “in-line” rating to an “outperform” rating and set a $102.00 target price for the company in a research note on Monday, October 16th. BMO Capital Markets raised their target price on shares of bluebird bio from $134.00 to $162.00 and gave the company a “buy” rating in a research note on Monday, October 30th. Finally, Goldman Sachs Group reaffirmed a “buy” rating and set a $186.00 target price on shares of bluebird bio in a research note on Friday, October 6th. Two analysts have rated the stock with a sell rating, ten have given a hold rating and thirteen have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $157.45.

In related news, insider Nick Leschly sold 7,050 shares of the firm’s stock in a transaction that occurred on Monday, October 23rd. The shares were sold at an average price of $145.14, for a total value of $1,023,237.00. Following the sale, the insider now owns 259,059 shares in the company, valued at $37,599,823.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jeffrey T. Walsh sold 35,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $151.38, for a total transaction of $5,298,300.00. Following the completion of the sale, the insider now owns 62,305 shares in the company, valued at approximately $9,431,730.90. The disclosure for this sale can be found here. Insiders sold 211,445 shares of company stock worth $37,326,831 in the last 90 days. 3.90% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently modified their holdings of the stock. Hanseatic Management Services Inc. boosted its holdings in bluebird bio by 0.3% in the second quarter. Hanseatic Management Services Inc. now owns 10,436 shares of the biotechnology company’s stock worth $1,096,000 after purchasing an additional 27 shares during the last quarter. Cornerstone Capital Management Holdings LLC. boosted its holdings in bluebird bio by 0.8% in the second quarter. Cornerstone Capital Management Holdings LLC. now owns 17,955 shares of the biotechnology company’s stock worth $1,885,000 after purchasing an additional 140 shares during the last quarter. Prudential Financial Inc. boosted its holdings in bluebird bio by 4.0% in the second quarter. Prudential Financial Inc. now owns 3,882 shares of the biotechnology company’s stock worth $408,000 after purchasing an additional 150 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in bluebird bio by 0.5% in the second quarter. The Manufacturers Life Insurance Company now owns 31,433 shares of the biotechnology company’s stock worth $3,302,000 after purchasing an additional 151 shares during the last quarter. Finally, Amalgamated Bank boosted its holdings in bluebird bio by 3.3% in the second quarter. Amalgamated Bank now owns 5,232 shares of the biotechnology company’s stock worth $550,000 after purchasing an additional 168 shares during the last quarter.

Shares of bluebird bio (BLUE) traded down $7.35 during midday trading on Friday, hitting $163.35. 1,753,800 shares of the company’s stock were exchanged, compared to its average volume of 743,860. bluebird bio has a fifty-two week low of $63.90 and a fifty-two week high of $222.03. The company has a market capitalization of $7,490.00, a P/E ratio of -23.30 and a beta of 2.08.

ILLEGAL ACTIVITY WARNING: This article was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://theolympiareport.com/2018/01/16/428715.html.

About bluebird bio

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Get a free copy of the Zacks research report on bluebird bio (BLUE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.